



Correction to: Strategies for Predicting Response to Checkpoint Inhibitors

Roberta Zappasodi^{1,2} · Jedd D. Wolchok^{1,2,3,4} · Taha Merghoub^{1,2,3}

Published online: 8 November 2018
© Springer Science+Business Media, LLC, part of Springer Nature 2018

Correction to: Curr Hematol Malig Rep (2018) 13:383–395
<https://doi.org/10.1007/s11899-018-0471-9>

The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below.

Conflict of Interest Jedd D. Wolchok is a consultant for Adaptive Biotech, Advaxis, Amgen, Apricity, Array BioPharma, Ascentage Pharma, Beigene, Bristol Myers Squibb, Celgene, Chugai, Elucida, Eli Lilly, F Star, Genentech, Imvaq, Kleo Pharma, MedImmune, Merck, Neon Therapeutics, Ono, Polaris Pharma, Polynoma, Psioxus, Puretech, Recepta, Trienza, Sellas Life Sciences, Serametrix, Surface Oncology, and Syndax and has received research support from Bristol Myers Squibb, Medimmune, Merck Pharmaceuticals, and Genentech. *Equity in:* Potenza Therapeutics, Tizona Pharmaceuticals, Adaptive Biotechnologies, Elucida, Imvaq, Beigene, and Trieza. Roberta Zappasodi and Taha Merghoub declare that they have no conflict of interest.

The online version of the original article can be found at <https://doi.org/10.1007/s11899-018-0471-9>

✉ Taha Merghoub
merghout@mskcc.org

¹ Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

² Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

³ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

⁴ Weill Cornell Medicine, New York, NY 10065, USA